Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients.
Éva Anna PirosÁkos SzabóFanni RenczValentin BrodszkyKlára SzalaiNoémi GalajdaBálint SzilveszterEdit DósaBéla MerkelyPéter HollóPublished in: Life (Basel, Switzerland) (2021)
By reducing the inflammation of the vascular wall, anti-IL-17 therapy may have a beneficial long-term effect on cardiovascular complications of systemic inflammation.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- rheumatoid arthritis
- peritoneal dialysis
- early onset
- risk factors
- stem cells
- cardiovascular disease
- patient reported outcomes
- disease activity
- ankylosing spondylitis
- metabolic syndrome
- systemic lupus erythematosus
- cell therapy